Press Coverage
Sofinnova Crossover
Tom Burt, partner at Sofinnova Partners, speaks at Edison Group’s Open House Global Healthcare Event
Related Strategy
CrossoverTom Burt, partner at Sofinnova Partners, joined Edison Group’s Open House Global Healthcare Event. His panel discussed some of the scenarios that are likely to play out in 2022 for biotech in public and private equity markets and M&A. View the replay here.
Related News
Sofinnova Partners portfolio company Amolyt Pharma to be acquired by AstraZeneca
Amolyt Pharma enters into definitive agreement to be acquired by AstraZeneca
Sensorion announces it has met primary endpoint for SENS-401 Phase 2a Clinical Study for residual hearing preservation
Mainstay Medical announces US$125 million equity financing transaction
Mainstay Medical announces receipt of FDA approval for MRI labeling on ReActiv8® Restorative Neurostimulation System